Calling All Derms! Chronic Spontaneous Urticaria Is For You!
At the 2024 ODAC Dermatology, Aesthetic & Surgical Conference, we were lucky to learn about the management of chronic spontaneous urticaria (CSU) from the renowned researcher and clinician, Dr. Adam J. Friedman, Professor and Chair of Dermatology at The George Washington University School of Medicine and Health Sciences. CSU can be a frustrating, exhausting condition for patients to endure, wi …
At the 2024 ODAC Dermatology, Aesthetic & Surgical Conference, we were lucky to learn about the management of chronic spontaneous urticaria (CSU) from the renowned researcher and clinician, Dr. Adam J. Friedman, Professor and Chair of Dermatology at The George Washington University School of Medicine and Health Sciences. CSU can be a frustrating, exhausting condition for patients to endure, wi … Continue reading "Calling All Derms! Chronic Spontaneous Urticaria Is For You!"
Introducing the April 2024 Editorial Highlights from the Journal of Drugs in Dermatology! This month's issue is packed with groundbreaking research and insights into dermatologic treatments and practices. From original articles exploring innovative therapies for conditions like photoaging and acne vulgaris to case reports shedding light on rare dermatologic phenomena, this issue offers a comprehen … 
At ODAC 2023, we had the opportunity to learn about the latest in treatments for blistering diseases from Dr. Karl Saardi, Associate Professor and Director of Inpatient Dermatology at George Washington University. We focused on the pemphigus and pemphigoid group of diseases, which we will review and summarize here.
Pemphigus
The pemphigus group of diseases is characterized by intraepidermal auto … 
Chronic idiopathic urticaria is urticaria for greater than 6 weeks without an identifiable trigger. Cases relapse in 20% of patients for more than 5 years and be difficult to manage; however, omalizumab is a recently approved option for treatment of chronic idiopathic urticaria showing beneficial outcomes.1 Omalizumab is an injectable monoclonal antibody that has been FDA approved not just for chr … 